Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8506222 | 0.89 | TP53 (0.32) | CA2TP53 | |
| Sulfuric Acid SCHEMBL8718724 | 0.81 | CA5A (0.46) | CA2TP53TSHRTDP1 | |
| Sulfuric Acid SCHEMBL1892151 | 0.81 | CA5A (0.46) | CA2TP53TSHRTDP1 | |
| E968 SCHEMBL31738448 | 0.80 | LMNA (0.38) | CA2TP53TSHRTDP1 | |
| Glycerin SCHEMBL720026 | 0.80 | LMNA (0.50) | CA2TP53TSHRTDP1 | |
| Propylene Glycol SCHEMBL28667172 | 0.78 | TDP1 (0.53) | CA2TP53TSHRTDP1 | |
| SCHEMBL9651406 | 0.78 | TSHR (0.36) | CA2TP53TSHRTDP1 | |
| Ethylene Glycol SCHEMBL7202667 | 0.78 | CA2 (0.41) | CA2TSHRTDP1 | |
| Ethylene Glycol SCHEMBL921115 | 0.78 | CA2 (0.41) | CA2TSHRTDP1 | |
| SCHEMBL56331 | 0.77 | CA2 (0.54) | CA2TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1614432-A2 | Method for treating amyloidosis | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-01-11 | — | — | EP | claimed |
| EP-1064013-A4 | $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2005-05-11 | — | — | EP | claimed |
| EP-1064013-A1 | $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | University of Washington (US) | 2001-01-03 | — | — | EP | claimed |
| WO-1999045947-A1 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIVERSITY OF WASHINGTON (US) | 1999-09-16 | — | — | WO | claimed |
| US-5840294-A | INHIBITING AMYLOID DEPOSITION BY ADMINISTERING A THERAPEUTIC COMPOUND COMPRISING AN ANIONIC GROUP AND A CARRIER MOLECULE | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-11-24 | — | — | US | claimed |
| US-7311893-B2 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-12-25 | — | — | US | disclosed |
| US-7148001-B2 | In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of Alzheimer's and Prion diseases | UNIVERSITY OF WASHINGTON (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1614432-A2 | Method for treating amyloidosis | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-01-11 | — | — | EP | disclosed |
| EP-1064013-A4 | $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2005-05-11 | — | — | EP | disclosed |
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-03-03 | — | — | US | disclosed |
| EP-1303311-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | Neurochem, Inc. (CA) | 2003-04-23 | — | — | EP | disclosed |
| US-20020168753-A1 | In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of Alzheimer's and Prion diseases | NATIONAL INSTITUTES OF HEALTH | 2002-11-14 | — | — | US | disclosed |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (GI) | 2002-08-22 | — | — | US | disclosed |
| WO-2002007781-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | NEUROCHEM INC. (CA) | 2002-01-31 | — | — | WO | disclosed |
| EP-1064013-A1 | $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | University of Washington (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999045947-A9 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999045947-A1 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIVERSITY OF WASHINGTON (US) | 1999-09-16 | — | — | WO | disclosed |
| US-5840294-A | INHIBITING AMYLOID DEPOSITION BY ADMINISTERING A THERAPEUTIC COMPOUND COMPRISING AN ANIONIC GROUP AND A CARRIER MOLECULE | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | APP, APBA1, BACE1 | CA2 2814/4885TP53 721/4885TSHR 4314/4885 |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | APP, APBA1, BACE1 | CA2 2814/4885TP53 721/4885TSHR 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.